Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer
Clinicaltrials.gov identifier:
NCT04895722
Stage 4 colorectal cancer
Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer
About the Study
This study is no longer recruiting patients.
The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus four other treatments in patients with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient () ( IV) Colorectal Cancer.
This is phase 2, multi-arm, , study. Participants are placed into one of the five study groups by chance. All study participants will know which medication they are receiving during the study.
This study is no longer recruiting patients.
This study is no longer recruiting patients.